Beasley David W C, Li Li, Suderman Miguel T, Guirakhoo Farshad, Trent Dennis W, Monath Thomas P, Shope Robert E, Barrett Alan D T
Department of Pathology, Sealy Center for Vaccine Development, and Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, 301 University Blvd., Galveston, TX 77555-0609, USA.
Vaccine. 2004 Sep 9;22(27-28):3722-6. doi: 10.1016/j.vaccine.2004.03.027.
The ability of antisera raised against a candidate Japanese encephalitis virus (JEV) vaccine, ChimeriVax-JE, and the currently licensed vaccine, JE-VAX, to protect against strains of JEV representing the four major genotypes was assessed. Neutralization assays and passive protection studies in mice showed that greatest protection was provided against strains of genotypes II and III, although some protection was also afforded against genotypes I and IV strains. ChimeriVax-JE stimulated protection that was comparable or superior to the JE-VAX control.
评估了针对候选日本脑炎病毒(JEV)疫苗ChimeriVax-JE和当前已获许可的疫苗JE-VAX产生的抗血清对代表四种主要基因型的JEV毒株的防护能力。在小鼠中进行的中和试验和被动保护研究表明,对基因型II和III的毒株提供了最大程度的保护,尽管对基因型I和IV的毒株也有一定程度的保护。ChimeriVax-JE激发的保护作用与JE-VAX对照相当或更优。